Immune booster combined with checkpoint blocker improves survival in metastatic melanoma
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, ...
Nov 4, 2014
0
0